Cardiovascular consequences of renal anaemia and erythropoietin therapy

Nephrology Dialysis Transplantation

Volumn 14, Issue 5, 1999, Pages 1317-1323

  Eckardt, Kai Uwe ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Anaemia; Cardiac ischaemia; Erythropoietin; Uraemic cardiomyopathy

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CASE REPORT; HEMODIALYSIS; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL;

EID: 0032919362     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/14.5.1317     Document Type: Article

References (64)

1. Pastan S, Bailey J. Dialysis therapy. N Engl J Med 1998; 338: 1428-1437
2. Mall G, Rambausek M, Neumeister A et al. Myocardial interstitial fibrosis in experimental uremia - implications for cardiac compliance. Kidney Int 1988; 33: 804-811
3. Mall G, Huther W, Schneider J et al. Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant 1990; 5: 39-44
4. Ikram H, Lynn KL, Bailey RR et al. Cardiovascular changes in chronic hemodialysis patients. Kidney Int 1983; 24: 371-376
5. Rostand SG, Kirk KA, Rutsky EA. Dialysis-associated ischemic heart disease: Insights from coronary angiography. Kidney Int 1984; 25: 653-659
6. Amann K, Wiest G, Zimmer G et al. Reduced capillary density in the myocardium of uremic rats - a stereological study. Kidney Int 1992; 42: 1079-1085
7. Raine AEG, Seymour A-ML, Roberts AFC et al. Impairment of cardiac function and energetics in experimental renal failure. J Clin Invest 1993; 92: 2934-2940
8. Foley RN, Parfrey PS, Harnett JD et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-192
9. Greaves SC, Gamble GD, Collins JF et al. Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure. Am J Kid Dis 1994; 24: 768-776
10. Parfrey PS, Foley RN, Harnett JD et al. Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant 1996; 11: 1277-1285
11. Silberberg JS, Barre PE, Prichard SS et al. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1988; 36: 286-290
12. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339: 799-805
13. Renal Data System. USRDS 1997 annual data report Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases 1997; D1-D51
14. Neill WA, Oxendine JM, Moore SC. Acute and chronic cardiovascular adjustments to induced anemia in dogs. Am J Physiol 1969; 217: 710-714
15. Schwartz S, Frantz RA, Shoemaker WC. Sequential hemodynamic and oxygen transport responses in hypovolemia, anemia, and hypoxia. Am J Physiol 1981; 241: H864-H871
16. Roy SB, Bhatia ML, Mathur VS et al. Hemodynamic effects of chronic severe anemia. Circulation 1963; 28: 346-356
17. Duke M, Abelmann WH. The hemodynamic response to chronic anemia. Circulation 1969; 39: 503-515
18. Olivetti G, Quaini F, Lagrasta C et al. Myocyte cellular hypertrophy and hyperplasia contribute to ventricular wall remodeling in anemia-induced cardiac hypertrophy in rats. Am J Pathol 1992; 141: 227-239
19. London GM, Fabiani F, Marchais SJ et al. Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. Kidney Int 1987; 31: 973-980
20. Levin A, Singer J, Thompson CR et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kid Dis 1996; 27: 347-354
21. Foley RN, Parfrey PS, Harnett JD et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kid Dis 1996; 28: 53-61
22. Madore F, Lowrie EG, Brugnara C et al. Anemia in hemodialysis patients: variables affecting this outcome predictor. JASN 1997; 8: 1921-1929
23. Wizemann V, Kaufmann J, Kramer W. Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease. Nephron 1992; 62: 161-165
24. Macdougall IC, Lewis NP, Saunders MJ et al. Long-term cardiorespiratory effects of amelioration of renal anemia by erythropoietin. Lancet 1990; 335: 489-493
25. Neff MS, Kwan EK, Persoff M et al. Hemodynamics of uremic anemia. Circulation 1971; 43: 876-883
26. Sikole A, Polenakovic M, Spirovska V et al. Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artif Organs 1993; 17: 977-984
27. Löw-Friedrich I, Grützmacher P, März W et al. Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients. Am J Nephrol 1991; 11: 54-60
28. Cannella G, LaCanna G, Sandrini M et al. Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients. Clin Nephrol 1990; 34: 272-282
29. London GM, Zins B, Pannier B et al. Vascular changes in hemodialysis patients in response to reombinant human erythropoietin. Kidney Int 1989; 36: 878-882
30. Löw I, Grützmacher P, Bergmann M et al. Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin. Clin Nephrol 1988; 31: 26-30
31. Martinez-Vea A, Bardaji A, Garcia C et al. Long-term myocardial effects of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis. Am J Kid Dis 1992; 19: 353-357
32. Fellner SK, Lang RM, Neumann A et al. Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin. Kidney Int 1993; 44: 1309-1315
33. Wizemann V, Schäfer R, Kramer W. Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left-ventricular hypertrophy. Nephron 1993; 64: 202-206
34. Silberberg J, Racine M, Barre P et al. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 1990; 6: 1-4
35. Fernandez A, Vega N, Jimenez F et al. Effect of recombinant human erythropoietin treatment on hemodynamic parameters in continuous ambulatory peritoneal dialysis and hemodialysis patients. Am J Nephrol 1992; 12: 207-211
36. Pascual J, Teruel JL, Marcen R et al. Hemodynamic and cardiac effects of erythropoietin in patients on regular dialysis. Int J Artif Organs 1992; 15: 349-353
37. Zehnder C, Zuber M, Sulzer M et al. Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients. Nephron 1992; 61: 21-25
38. Goldberg N, Lundin P, Delano B et al. Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin. Am Heart J 1992; 124; 424-427
39. Pascual J, Teruel JL, Moya JL et al. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol 1991; 35: 280-287
40. Monrad ES, Hess OM, Murakami T et al. Time course of regression of left ventricular hypertrophy after aortic valve replacement. Circulation 1988; 77: 1345-1355
41. Cannella G, Paoletti E, Delfineo R et al. Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int 1993; 44: 881-886
42. Radermacher J, Koch KM. Treatment of renal anemia by erythropoietin substitution - The effects on the cardiovascular system. Clin Nephrol 1995; 44: S56-S60
43. Potolés J, Torralbo A, Martin P et al. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kid Dis 1997; 29: 541-548
44. Mann JFE. Hypertension and cardiovascular effects - long term safety and potential long-term benefits of r-HuEPO. Nephrol Dial Transplant 1995; 10: 80-84
45. Raine AEG, Roger SD. Effects of erythropoietin on blood pressure. Am J Kid Dis 1991; 18: 76-83
46. Radermacher J, Koch KM. Erythropoietin and Hypertension. In: Bauer C, Koch KM, Scigalla P, Wieczorek L. eds. Erythropoietin - Molecular Physiology and Clinical Application. Marcel, Dekker, New York, Basel, Hong Kong: 1993; 129-150
47. Touam M, Olivia JP, Zingraff J et al. Does intravenous erythropoietin lead to an immediate, transient increase in arterial blood pressure in dialysis patients? Nephron 1994; 67: 240-241
48. Roger SD, Grasty MS, Baker LRI et al. Effects of oxygen breathing and erythropoietin on hypoxic vasodilatation in uremic anemia. Kidney Int 1992; 42: 975-980
49. Heidenreich S, Rahn K-H, Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 1991; 39: 259-265
50. Tsukada H, Ishimitsu T, Ogawa Y et al. Direct vasopressor effects of erythropoietin in genetically hypertensive rats. Life Sci 1993; 52: 1425-1434
51. Carlini RG, Dusso AS, Obialo CI et al. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int 1993; 43: 1010-1014
52. Neusser M, Tepel M, Zidek W. Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells. Cardiovasc Res 1993; 27: 1233-1236
53. Katch K, Mizuno K, Hashimoto S et al. Direct evidence for erythropoietin-induced release of endothelin from peripheral vascular tissue. Life Sci 1994; 54: PL253-PL259
54. Gogusev J, Zhu D-L, Hérembert T et al. Effect of erythropoietin on DNA synthesis, proto-oncogene expression and phospholipase C activity in rat vascular smooth muscle cells. Biochem Biophys Res Commun 1994; 199: 977-983
55. Haller H, Christel C, Dannenberg L et al. Signal transduction of erythropoietin in endothelial cells. Kidney Int 1996; 50: 481-488
56. Nissenson AR, Besarab A, Bolton WK et al. Target haematocrit during erythropoietin therapy. Nephrol Dial Transplant 1997; 12: 1813-1816
57. Eschbach JW, Egrie JC, Downing MR et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 1987; 316: 73-78
58. Eckardt K-U. Erythropoietin: oxygen-dependent control of erythropoiesis and its failure in renal disease. Nephron 1994; 67: 7-23
59. Canadian erythropoietin study group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. Br Med J 1990; 300: 573-578
60. 2 transport during exercise in patients with chronic renal failure. J Clin Invest 1996; 97: 2092-2100
61. Moore GE, Bertocci LA, Painter PL. 31P-magnetic resonance spectroscopy assessment of subnormal oxidative metabolism in skeletal muscle of renal failure patients. J Clin Invest 1993; 91: 420-424
62. McMahon LP, McKenna MJ, Sangkabutra T et al. Physical performance and associated electrolyte changes after haemoglobin normalization: a comparative study in haemodialysis patients. Nephrol Dial Transplant 1999; in press:
63. Besarab A, Bolton K, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339, 584-590
64. Macdougall IC, Ritz E. The normal haematocrit trial in dialysis patients with cardiac disease: are we any the less confused about target haemoglobin? Nephrol Dial Transplant 1998; 13: 3030-3033